Jersey Health Investigates Death Tied to Cannabis Prescription Gaps

Death Investigation Triggers Prescribing Review

Jersey Health opened a formal investigation into a patient death involving medical cannabis after identifying systemic failures in prescription monitoring and follow-up care. The department disclosed the case September 28. It didn't release the patient's age, diagnosis, or date of death. Officials confirmed the review is examining whether prescribing physicians adhered to the island's medical cannabis protocols, which require quarterly patient assessments and coordination with specialist clinics.

At issue: whether the prescribing chain—from initial authorization to dispensing—followed Jersey's 2019 medical cannabis framework. That framework mandates that only registered specialists can authorize cannabis for conditions including chronic pain, multiple sclerosis, and treatment-resistant epilepsy. GPs can continue prescriptions but can't initiate them.

Jersey legalized medical cannabis in November 2019, making it one of the first British Crown Dependencies to do so. Patients obtain prescriptions from UK-registered specialists, then fill them at island pharmacies licensed to dispense cannabis oils and flower.

Prescribing Gaps Include Missing Follow-Up and Dosing Records

Health officials identified three critical gaps: incomplete patient follow-up schedules, missing dosage titration records, and unclear lines of clinical responsibility when patients transition from specialist to GP care. Some patients received repeat prescriptions without the required quarterly reviews, according to the disclosure, and dosing adjustments weren't consistently documented in electronic health records.

How many patients are affected? The department didn't say. Jersey's medical cannabis patient count hasn't been publicly reported since 2024, when officials estimated fewer than 200 active prescriptions island-wide. Without a centralized patient registry—a feature present in Germany's and Australia's programs—tracking prescription continuity and adverse events has proven difficult.

Prescribing responsibility often shifts from specialists to GPs after initial titration, but the handoff protocol lacks formal documentation requirements. That gap becomes acute when patients source cannabis from multiple suppliers or adjust dosing independently, a behavior observed in other jurisdictions with loose monitoring frameworks.

Next Steps and Policy Implications

Health and Community Services plans to release updated prescribing guidelines by November 2026 and is exploring a mandatory patient registry to close monitoring gaps. Officials are also reviewing whether to require pharmacies to report dispensing data directly to health authorities—a practice standard in Canada and Israel but not yet adopted in Jersey.

For context on medical cannabis safety frameworks, see the CannIntel topic hub on medical cannabis prescribing safety.

The investigation's findings will be presented to Jersey's Health and Social Security Scrutiny Panel, which has oversight authority over the island's controlled-drug policies. No public hearing has been scheduled yet.

The next signal: whether Jersey implements real-time prescription monitoring or continues relying on retrospective audits. That choice determines whether the system can catch dosing errors before they escalate.